查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1445548

甲真菌病市场评估：按治疗类型、适应症、分销管道和地区划分的机会和预测（2017-2031）

Onychomycosis Market Assessment, By Treatment Type, By Indication, By Distribution Channel, By Region, Opportunities and Forecast, 2017-2031F
出版日期: | 出版商: Market Xcel - Markets and Data | 英文 224 Pages | 商品交期: 3-5个工作天内

价格

全球甲真菌病市场规模将从2023年的40.1亿美元增长到2031年的61.7亿美元，2024-2031年预测期内复合年增长率为5.53%，预计规模还将继续增长。

甲真菌病市场的驱动因素包括甲真菌病的高患病率、由于免疫力下降而更容易患甲真菌病的老年人口的增加、医疗基础设施的显着发展以及行业内缺乏新产品核准。受成长等因素驱动。 片剂、乳膏、喷雾剂和注射剂等抗真菌製剂以及类固醇和抗生素等药物类别可用于治疗甲癣。

甲癣盛行率增加

由于老化、末梢循环不良、糖尿病、缺乏运动、足部护理不足等因素，全球甲癣的盛行率正稳定上升。 反覆的指甲外伤、长期暴露于病原真菌、免疫系统减弱、共用洗浴设施也会导致甲癣的流行。 此外，由于指甲生长缓慢、血液供应不良以及经常留在黑暗、潮湿的环境中等因素，甲癣在脚趾甲中比手指甲更常见。 儘管甲癣不会危及生命，但它是一个重要的公共卫生问题，因为它会引起疼痛并干扰工作和社交生活。 这种疾病盛行率的上升正在推动市场对相关产品和服务的需求。

高龄化社会与糖尿病患者的负担

甲癣的发生在老年族群中非常常见，原因是免疫系统减弱。 糖尿病患者表现出多种有利于甲癣发展的临床状况，包括高水平的糖化血红蛋白 (HbA1C) 和长期的糖尿病状态，导致指甲加速增厚和甲癣。 随着全球老年人口和糖尿病患者数量的大幅增加，甲真菌病的市场需求预计也会增加，进一步扩大市场成长。

根据CDC发布的《国家糖尿病统计报告》，成人糖尿病盛行率随着年龄的增长而增加，65岁以上人口中糖尿病盛行率约为29.2%。 近 20% 的甲癣患者年龄超过 60 岁。 据估计，大约三分之一的糖尿病患者可能患有甲癣。

亚太地区正在成为一个快速成长的地区

亚太地区预计将成为成长最快的地区。 这是由于老年人口不断增长、糖尿病患病率上升以及其他与真菌感染相关的危险因素、医疗基础设施改善以及社区对指甲健康和真菌感染的认识提高等因素造成的。 该地区製药公司的发展以及具有成本效益的治疗方案的提供也促进了该地区的成长。 根据 Blueberry Therapeutics 的数据，北美甲癣的盛行率约为 14%，而亚太地区甲癣的盛行率约为 20%。

本报告调查了全球甲癣市场，提供了市场定义和概述、市场规模趋势和预测、各个细分市场和地区的详细分析、行业结构以及影响市场成长的因素。我们编制了分析、案例研究、竞争格局、主要公司的简介等等。

目录

第1章研究方法

第 2 章专案范围与定义

第 3 章执行摘要

第4章全球甲癣市场展望

  • 市场规模/预测
  • 依治疗类型
    • 药物
    • 雷射治疗
    • 光动力疗法
  • 依指示
    • 远端甲下甲癣
    • 白色浅层甲癣
    • 近端甲下甲癣
    • 念珠菌甲癣
    • 完全营养不良型甲真菌病
  • 按分销管道
    • 医院
    • 皮肤科诊所
    • 零售药局
    • 网路药局
  • 按地区
    • 北美
    • 欧洲
    • 亚太地区
    • 南美洲
    • 中东/非洲
  • 各公司的市占率

第 5 章全球甲癣市场展望：按地区

  • 北美
  • 欧洲
  • 亚太地区
  • 南美洲
  • 中东/非洲

第 6 章市场映射

  • 依治疗类型
  • 依指示
  • 按分销管道
  • 按地区

第7章宏观环境与产业结构

  • 需求与供给分析
  • 汇入/汇出分析
  • 价值链分析
  • PESTEL 分析
  • 波特五力分析

第 8 章市场动态

  • 成长驱动因素
  • 生长抑制因子（问题/抑制因素）

第 9 章监理架构与创新

  • 临床试验
  • 专利情况
  • 监理机关的核准
  • 创新/新兴技术

第10章主要公司状况

  • 前 5 名市场领导者的竞争矩阵
  • 前 5 位市场领导者的市场收入分析
  • 併购/合资企业（如果适用）
  • SWOT 分析（5 家参与公司）

第11章价格分析

第 12 章案例研究

第13章主要公司展望

  • Bausch Health Companies Inc.
  • Abbott Laboratories
  • Pfizer Inc.
  • Bayer AG
  • Teva Pharmaceutical Industries Ltd.
  • Cipla Inc.
  • Merck & Co., Inc.
  • Novartis AG
  • Sun Pharmaceutical Industries Ltd.
  • GlaxoSmithKline plc.

第 14 章策略建议

第15章关于我们公司/免责声明

Product Code: MX11097

Global onychomycosis market is projected to witness a CAGR of 5.53% during the forecast period 2024-2031, growing from USD 4.01 billion in 2023 to USD 6.17 billion in 2031. Onychomycosis market is majorly driven by the high prevalence of onychomycosis, increasing geriatric population that is more prone to such disorders due to the weakened immune system, significant developments in the healthcare infrastructure, and increasing approvals of novel products in the industry. Antifungal preparations like tablets, creams, sprays, and injections, along with other drug classes like steroids and antibiotics, are used for the treatment of onychomycosis. The ability of fungal species to spread quickly through various means like air, water, touch, sharing personal belongings, and using public spaces like swimming pools is the major concern for widespread onychomycosis infection. However, post-COVID awareness about social distancing and growing hygienic practices reduces the risk of onychomycosis and further limit the growth of the market. Additionally, side effects associated with these drugs and therapies and growing antifungal resistance are some major restraints for the market.

In January 2024, Vanda Pharmaceuticals announced that it had received US FDA approval to begin with an investigational new drug (IND) VTR-297, which is a topical antifungal drug candidate for the treatment of onychomycosis. VTR-297 is a histone deacetylase (HDAC) inhibitor with promising antifungal activity against dermatophytes and other fungi. This molecule was originally isolated from the yeast species Streptomyces hygroscopicus as an antifungal antibiotic.

Growing Prevalence of Onychomycosis

The global prevalence of onychomycosis is steadily increasing due to factors such as age, poor peripheral circulation, diabetes, inactivity, and the inability to maintain good foot care. Recurrent nail trauma, longer exposure to pathogenic fungi, suboptimal immune function, and shared bathing facilities are some other reasons for the spread of onychomycosis. Additionally, fungal nail infections are more common in toenails than fingernails due to their slower growth, reduced blood supply, and frequent confinement in dark, moist environments. While onychomycosis is not life-threatening, it can cause pain and potentially undermine work and social lives, making it an important public health problem. The rising prevalence of the disease drives the demand for relevant products and services in the market.

As per an article published in the Journal of Fungi, in May 2023, the global prevalence of onychomycosis was somewhere around 10% and this infection accounted for up to 50% of all nail diseases. Dermatophytes species Trichophyton rubrum and Trichophyton mentagrophytes are common causative agents of onychomycosis, responsible for 60-70% of infections. While yeasts are responsible for approximately 20% of onychomycosis, non-dermatophytes cause the remaining 10%.

Aging Population and Diabetic Disease Burden

The occurrence of onychomycosis is very common in the geriatric population, the reason being the weakened immune system. Diabetic patients present several clinical conditions that favor the development of onychomycosis, including high levels of glycated hemoglobin (HbA1C) and prolonged diabetic status leading to nail thickness and acceleration of nail plate involvement. As the global geriatric population and diabetic disease both are rising significantly, the market demand for onychomycosis is expected to rise as well, further expanding the market growth.

As per the National Diabetes Statistics Report published by the CDC, the prevalence of diabetes in adults increases with age, reaching about 29.2% among those aged 65 years or older. Nearly 20% of the population suffering from onychomycosis is aged above 60 years. Around one-third of diabetic patients are likely to suffer from onychomycosis.

Dominance of Orally Administered Drugs Segment

One of the major onychomycosis market trends is the rising dominance of orally administered drugs over other routes of administration. Orally administered drugs are highly preferred due to their better effectiveness and shorter treatment duration compared to topically applied drugs. Oral antifungal medications like terbinafine and azoles are highly effective treatments for the clinical cure of onychomycosis. They have been found to have higher cure rates compared to topical preparations, which traditionally have low success rates due to the physical hindrance of the nail. Most of the marketed formulations are meant for oral administration only, although a few topical formulations like nail lacquer and sprays also hit the market in recent times.

For instance, in February 2024, Moberg Pharma AB launched MOB-015 under the Terclara brand in partnership with Allderma AB in the Swedish market. The launched drug is witnessing significant traction from the market as it is highly effective against nail fungus and conditions such as onychomycosis. Moberg Pharma estimated the sales potential of MOB-015 at the global level to be around USD 250-500 million.

The Popularity of Distal Subungual Onychomycosis as the Leading Type

Distal subungual onychomycosis is anticipated to be the leading type of onychomycosis occurring among individuals globally since it is the most diagnosed type of onychomycosis. Distal subungual initiates under the edge of the nail or alongside the lateral edges. It is further characterized by the accumulation of debris under the nail, resulting in yellowish, thickened, and brittle toenails. Around 90% of the onychomycosis cases are comprised of distal subungual onychomycosis. Market players are actively designing efficient products for its treatment.

For instance, in November 2023, Blueberry Therapeutics Limited reported that BB2603, a novel topical terbinafine antifungal medication, has demonstrated superiority over placebo (vehicle) with a high degree of statistical significance in the Phase 2b trial (BBTAF202) in patients with onychomycosis, meeting the primary endpoint. 111 participants with mild to moderate distal subungual onychomycosis of the toenail were included in the BBTAF202 European trial. This study evaluated the pharmacokinetics, safety, and effectiveness of BB2603-10 twice daily for three months in comparison to a vehicle, as well as two lower formulation strengths of BB2603-3 and BB2603-1. Successful completion of this trial is anticipated to add another promising product to the market.

Asia-Pacific to be the Fastest-Growing Region

Asia-Pacific is expected to be the fastest-growing region for the onychomycosis market. This is due to factors such as the increasing geriatric population, rising prevalence of diabetes and other risk factors associated with fungal infections, improving healthcare infrastructure, and growing awareness about nail health and fungal infections in the region. The expansion of pharmaceutical companies in the region and the availability of cost-effective treatment options also contribute to the market growth in Asia Pacific. According to Blueberry Therapeutics, the prevalence of onychomycosis in Asia Pacific is around 20%, while in North America, the prevalence of onychomycosis is around 14%.

Future Market Scenario

Terbinafine resistance being the major concern related to onychomycosis treatment needs to be addressed through a shift towards azole-based formulations, which may drive innovation in the future of onychomycosis treatment. Market approval and good marketing strategy for azole-based drugs like Fosravuconazole, Posaconazole, Oteseconazole, and other related compounds is anticipated to expand the market further.

The growing popularity of photodynamic therapy and laser-assisted drug delivery methods have shown high efficacy in the treatment of onychomycosis. The future of the onychomycosis market has promising scope for these treatment options. For instance, according to an article published by 'Mycoses' journal in October 2023, with excellent performance, safety, and tolerability, photodynamic therapy, which uses a cream combining 0.1% w/w FMN or 2% w/w MB with 40% w/w urea, can be a very promising new topical treatment for toenail onychomycosis.

Key Players Landscape and Outlook

Bausch Health Companies Inc., Abbott Laboratories, Pfizer Inc., Bayer AG, Teva Pharmaceutical Industries Ltd., Cipla Inc., Merck & Co., Inc., Novartis AG, Sun Pharmaceutical Industries Ltd., and GlaxoSmithKline plc. are some of the leading players in the onychomycosis market with years of experience and trust. These companies are involved in the development and marketing of drugs, laser therapy, and photodynamic therapy for the treatment of onychomycosis. The key players have active involvement in intellectual property filings and clinical trials, which seems promising for the expansion of the market size.

In October 2023, Bausch Health filed a new patent for the treatment method for nail fungal onychomycosis. The method comprises the application of 10% efinaconazole formulation once a day for 36 weeks without removing the formulation from the nail. The formulation contains ingredients like alcohol, water, and citric acid.

Table of Contents

1. Research Methodology

2. Project Scope & Definitions

3. Executive Summary

4. Global Onychomycosis Market Outlook, 2017-2031F

  • 4.1. Market Size & Forecast
    • 4.1.1. By Value
    • 4.1.2. By Volume
  • 4.2. By Treatment Type
    • 4.2.1. Drugs
      • 4.2.1.1. Topical
      • 4.2.1.2. Oral
    • 4.2.2. Laser Therapy
      • 4.2.2.1. CO2 Ablative Lasers
      • 4.2.2.2. Nd: YAG Lasers
      • 4.2.2.3. Dual-wavelength near-infrared Lasers
    • 4.2.3. Photodynamic Therapy
  • 4.3. By Indication
    • 4.3.1. Distal Subungual Onychomycosis
    • 4.3.2. White Superficial Onychomycosis
    • 4.3.3. Proximal Subungual Onychomycosis
    • 4.3.4. Candidal Onychomycosis
    • 4.3.5. Total Dystrophic Onychomycosis
  • 4.4. By Distribution Channel
    • 4.4.1. Hospitals
    • 4.4.2. Dermatology Clinics
    • 4.4.3. Retail Pharmacies
    • 4.4.4. Online Pharmacies
  • 4.5. By Region
    • 4.5.1. North America
    • 4.5.2. Europe
    • 4.5.3. Asia-Pacific
    • 4.5.4. South America
    • 4.5.5. Middle East and Africa
  • 4.6. By Company Market Share (%), 2023

5. Global Onychomycosis Market Outlook, By Region, 2017-2031F

  • 5.1. North America*
    • 5.1.1. Market Size & Forecast
      • 5.1.1.1. By Value
      • 5.1.1.2. By Volume
    • 5.1.2. By Treatment Type
      • 5.1.2.1. Drugs
      • 5.1.2.1.1. Topical
      • 5.1.2.1.2. Oral
      • 5.1.2.2. Laser Therapy
      • 5.1.2.2.1. CO2 Ablative Lasers
      • 5.1.2.2.2. Nd: YAG Lasers
      • 5.1.2.2.3. Dual-wavelength near-infrared Lasers
      • 5.1.2.3. Photodynamic Therapy
    • 5.1.3. By Indication
      • 5.1.3.1. Distal Subungual Onychomycosis
      • 5.1.3.2. White Superficial Onychomycosis
      • 5.1.3.3. Proximal Subungual Onychomycosis
      • 5.1.3.4. Candidal Onychomycosis
      • 5.1.3.5. Total Dystrophic Onychomycosis
    • 5.1.4. By Distribution Channel
      • 5.1.4.1. Hospitals
      • 5.1.4.2. Dermatology Clinics
      • 5.1.4.3. Retail Pharmacies
      • 5.1.4.4. Online Pharmacies
    • 5.1.5. United States*
      • 5.1.5.1. Market Size & Forecast
      • 5.1.5.1.1. By Value
      • 5.1.5.1.2. By Volume
      • 5.1.5.2. By Treatment Type
      • 5.1.5.2.1. Drugs
      • 5.1.5.2.1.1. Topical
      • 5.1.5.2.1.2. Oral
      • 5.1.5.2.2. Laser Therapy
      • 5.1.5.2.2.1. CO2 Ablative Lasers
      • 5.1.5.2.2.2. Nd: YAG Lasers
      • 5.1.5.2.2.3. Dual-wavelength near-infrared Lasers
      • 5.1.5.2.3. Photodynamic Therapy
      • 5.1.5.3. By Indication
      • 5.1.5.3.1. Distal Subungual Onychomycosis
      • 5.1.5.3.2. White Superficial Onychomycosis
      • 5.1.5.3.3. Proximal Subungual Onychomycosis
      • 5.1.5.3.4. Candidal Onychomycosis
      • 5.1.5.3.5. Total Dystrophic Onychomycosis
      • 5.1.5.4. By Distribution Channel
      • 5.1.5.4.1. Hospitals
      • 5.1.5.4.2. Dermatology Clinics
      • 5.1.5.4.3. Retail Pharmacies
      • 5.1.5.4.4. Online Pharmacies
    • 5.1.6. Canada
    • 5.1.7. Mexico

All segments will be provided for all regions and countries covered

  • 5.2. Europe
    • 5.2.1. Germany
    • 5.2.2. France
    • 5.2.3. Italy
    • 5.2.4. United Kingdom
    • 5.2.5. Russia
    • 5.2.6. Netherlands
    • 5.2.7. Spain
    • 5.2.8. Turkey
    • 5.2.9. Poland
  • 5.3. Asia-Pacific
    • 5.3.1. India
    • 5.3.2. China
    • 5.3.3. Japan
    • 5.3.4. Australia
    • 5.3.5. Vietnam
    • 5.3.6. South Korea
    • 5.3.7. Indonesia
    • 5.3.8. Philippines
  • 5.4. South America
    • 5.4.1. Brazil
    • 5.4.2. Argentina
  • 5.5. Middle East & Africa
    • 5.5.1. Saudi Arabia
    • 5.5.2. UAE
    • 5.5.3. South Africa

6. Market Mapping, 2023

  • 6.1. By Treatment Type
  • 6.2. By Indication
  • 6.3. By Distribution Channel
  • 6.4. By Region

7. Macro Environment and Industry Structure

  • 7.1. Demand Supply Analysis
  • 7.2. Import Export Analysis
  • 7.3. Value Chain Analysis
  • 7.4. PESTEL Analysis
    • 7.4.1. Political Factors
    • 7.4.2. Economic System
    • 7.4.3. Social Implications
    • 7.4.4. Technological Advancements
    • 7.4.5. Environmental Impacts
    • 7.4.6. Legal Compliances and Regulatory Policies (Statutory Bodies Included)
  • 7.5. Porter's Five Forces Analysis
    • 7.5.1. Supplier Power
    • 7.5.2. Buyer Power
    • 7.5.3. Substitution Threat
    • 7.5.4. Threat from New Entrant
    • 7.5.5. Competitive Rivalry

8. Market Dynamics

  • 8.1. Growth Drivers
  • 8.2. Growth Inhibitors (Challenges and Restraints)

9. Regulatory Framework and Innovation

  • 9.1. Clinical Trials
  • 9.2. Patent Landscape
  • 9.3. Regulatory Approvals
  • 9.4. Innovations/Emerging Technologies

10. Key Players Landscape

  • 10.1. Competition Matrix of Top Five Market Leaders
  • 10.2. Market Revenue Analysis of Top Five Market Leaders (in %, 2023)
  • 10.3. Mergers and Acquisitions/Joint Ventures (If Applicable)
  • 10.4. SWOT Analysis (For Five Market Players)

11. Pricing Analysis

12. Case Studies

13. Key Players Outlook

  • 13.1. Bausch Health Companies Inc.
    • 13.1.1. Company Details
    • 13.1.2. Key Management Personnel
    • 13.1.3. Products & Services
    • 13.1.4. Financials (As reported)
    • 13.1.5. Key Market Focus & Geographical Presence
    • 13.1.6. Recent Developments
  • 13.2. Abbott Laboratories
  • 13.3. Pfizer Inc.
  • 13.4. Bayer AG
  • 13.5. Teva Pharmaceutical Industries Ltd.
  • 13.6. Cipla Inc.
  • 13.7. Merck & Co., Inc.
  • 13.8. Novartis AG
  • 13.9. Sun Pharmaceutical Industries Ltd.
  • 13.10. GlaxoSmithKline plc.

Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.

14. Strategic Recommendations

15. About Us & Disclaimer

List of Tables

  • Table 1. Pricing Analysis of Products from Key Players
  • Table 2. Competition Matrix of Top 5 Market Leaders
  • Table 3. Mergers & Acquisitions/ Joint Ventures (If Applicable)
  • Table 4. About Us - Regions and Countries Where We Have Executed Client Projects

List of Figures

  • Figure 1. Global Onychomycosis Market, By Value, in USD Billion, 2017-2031F
  • Figure 2. Global Onychomycosis Market, By Volume, in Million Units, 2017-2031F
  • Figure 3. Global Onychomycosis Market Share (%), By Treatment Type, 2017-2031F
  • Figure 4. Global Onychomycosis Market Share (%), By Indication, 2017-2031F
  • Figure 5. Global Onychomycosis Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 6. Global Onychomycosis Market Share (%), By Region, 2017-2031F
  • Figure 7. North America Onychomycosis Market, By Value, in USD Billion, 2017-2031F
  • Figure 8. North America Onychomycosis Market, By Volume, in Million Units, 2017-2031F
  • Figure 9. North America Onychomycosis Market Share (%), By Treatment Type, 2017-2031F
  • Figure 10. North America Onychomycosis Market Share (%), By Indication, 2017-2031F
  • Figure 11. North America Onychomycosis Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 12. North America Onychomycosis Market Share (%), By Country, 2017-2031F
  • Figure 13. United States Onychomycosis Market, By Value, in USD Billion, 2017-2031F
  • Figure 14. United States Onychomycosis Market, By Volume, in Million Units, 2017-2031F
  • Figure 15. United States Onychomycosis Market Share (%), By Treatment Type, 2017-2031F
  • Figure 16. United States Onychomycosis Market Share (%), By Indication, 2017-2031F
  • Figure 17. United States Onychomycosis Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 18. Canada Onychomycosis Market, By Value, in USD Billion, 2017-2031F
  • Figure 19. Canada Onychomycosis Market, By Volume, in Million Units, 2017-2031F
  • Figure 20. Canada Onychomycosis Market Share (%), By Treatment Type, 2017-2031F
  • Figure 21. Canada Onychomycosis Market Share (%), By Indication, 2017-2031F
  • Figure 22. Canada Onychomycosis Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 23. Mexico Onychomycosis Market, By Value, in USD Billion, 2017-2031F
  • Figure 24. Mexico Onychomycosis Market, By Volume, in Million Units, 2017-2031F
  • Figure 25. Mexico Onychomycosis Market Share (%), By Treatment Type, 2017-2031F
  • Figure 26. Mexico Onychomycosis Market Share (%), By Indication, 2017-2031F
  • Figure 27. Mexico Onychomycosis Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 28. Europe Onychomycosis Market, By Value, in USD Billion, 2017-2031F
  • Figure 29. Europe Onychomycosis Market, By Volume, in Million Units, 2017-2031F
  • Figure 30. Europe Onychomycosis Market Share (%), By Treatment Type, 2017-2031F
  • Figure 31. Europe Onychomycosis Market Share (%), By Indication, 2017-2031F
  • Figure 32. Europe Onychomycosis Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 33. Europe Onychomycosis Market Share (%), By Country, 2017-2031F
  • Figure 34. Germany Onychomycosis Market, By Value, in USD Billion, 2017-2031F
  • Figure 35. Germany Onychomycosis Market, By Volume, in Million Units, 2017-2031F
  • Figure 36. Germany Onychomycosis Market Share (%), By Treatment Type, 2017-2031F
  • Figure 37. Germany Onychomycosis Market Share (%), By Indication, 2017-2031F
  • Figure 38. Germany Onychomycosis Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 39. France Onychomycosis Market, By Value, in USD Billion, 2017-2031F
  • Figure 40. France Onychomycosis Market, By Volume, in Million Units, 2017-2031F
  • Figure 41. France Onychomycosis Market Share (%), By Treatment Type, 2017-2031F
  • Figure 42. France Onychomycosis Market Share (%), By Indication, 2017-2031F
  • Figure 43. France Onychomycosis Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 44. Italy Onychomycosis Market, By Value, in USD Billion, 2017-2031F
  • Figure 45. Italy Onychomycosis Market, By Volume, in Million Units, 2017-2031F
  • Figure 46. Italy Onychomycosis Market Share (%), By Treatment Type, 2017-2031F
  • Figure 47. Italy Onychomycosis Market Share (%), By Indication, 2017-2031F
  • Figure 48. Italy Onychomycosis Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 49. United Kingdom Onychomycosis Market, By Value, in USD Billion, 2017-2031F
  • Figure 50. United Kingdom Onychomycosis Market, By Volume, in Million Units, 2017-2031F
  • Figure 51. United Kingdom Onychomycosis Market Share (%), By Treatment Type, 2017-2031F
  • Figure 52. United Kingdom Onychomycosis Market Share (%), By Indication, 2017-2031F
  • Figure 53. United Kingdom Onychomycosis Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 54. Russia Onychomycosis Market, By Value, in USD Billion, 2017-2031F
  • Figure 55. Russia Onychomycosis Market, By Volume, in Million Units, 2017-2031F
  • Figure 56. Russia Onychomycosis Market Share (%), By Treatment Type, 2017-2031F
  • Figure 57. Russia Onychomycosis Market Share (%), By Indication, 2017-2031F
  • Figure 58. Russia Onychomycosis Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 59. Netherlands Onychomycosis Market, By Value, in USD Billion, 2017-2031F
  • Figure 60. Netherlands Onychomycosis Market, By Volume, in Million Units, 2017-2031F
  • Figure 61. Netherlands Onychomycosis Market Share (%), By Treatment Type, 2017-2031F
  • Figure 62. Netherlands Onychomycosis Market Share (%), By Indication, 2017-2031F
  • Figure 63. Netherlands Onychomycosis Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 64. Spain Onychomycosis Market, By Value, in USD Billion, 2017-2031F
  • Figure 65. Spain Onychomycosis Market, By Volume, in Million Units, 2017-2031F
  • Figure 66. Spain Onychomycosis Market Share (%), By Treatment Type, 2017-2031F
  • Figure 67. Spain Onychomycosis Market Share (%), By Indication, 2017-2031F
  • Figure 68. Spain Onychomycosis Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 69. Turkey Onychomycosis Market, By Value, in USD Billion, 2017-2031F
  • Figure 70. Turkey Onychomycosis Market, By Volume, in Million Units, 2017-2031F
  • Figure 71. Turkey Onychomycosis Market Share (%), By Treatment Type, 2017-2031F
  • Figure 72. Turkey Onychomycosis Market Share (%), By Indication, 2017-2031F
  • Figure 73. Turkey Onychomycosis Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 74. Poland Onychomycosis Market, By Value, in USD Billion, 2017-2031F
  • Figure 75. Poland Onychomycosis Market, By Volume, in Million Units, 2017-2031F
  • Figure 76. Poland Onychomycosis Market Share (%), By Treatment Type, 2017-2031F
  • Figure 77. Poland Onychomycosis Market Share (%), By Indication, 2017-2031F
  • Figure 78. Poland Onychomycosis Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 79. South America Onychomycosis Market, By Value, in USD Billion, 2017-2031F
  • Figure 80. South America Onychomycosis Market, By Volume, in Million Units, 2017-2031F
  • Figure 81. South America Onychomycosis Market Share (%), By Treatment Type, 2017-2031F
  • Figure 82. South America Onychomycosis Market Share (%), By Indication, 2017-2031F
  • Figure 83. South America Onychomycosis Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 84. South America Onychomycosis Market Share (%), By Country, 2017-2031F
  • Figure 85. Brazil Onychomycosis Market, By Value, in USD Billion, 2017-2031F
  • Figure 86. Brazil Onychomycosis Market, By Volume, in Million Units, 2017-2031F
  • Figure 87. Brazil Onychomycosis Market Share (%), By Treatment Type, 2017-2031F
  • Figure 88. Brazil Onychomycosis Market Share (%), By Indication, 2017-2031F
  • Figure 89. Brazil Onychomycosis Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 90. Argentina Onychomycosis Market, By Value, in USD Billion, 2017-2031F
  • Figure 91. Argentina Onychomycosis Market, By Volume, in Million Units, 2017-2031F
  • Figure 92. Argentina Onychomycosis Market Share (%), By Treatment Type, 2017-2031F
  • Figure 93. Argentina Onychomycosis Market Share (%), By Indication, 2017-2031F
  • Figure 94. Argentina Onychomycosis Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 95. Asia-Pacific Onychomycosis Market, By Value, in USD Billion, 2017-2031F
  • Figure 96. Asia-Pacific Onychomycosis Market, By Volume, in Million Units, 2017-2031F
  • Figure 97. Asia-Pacific Onychomycosis Market Share (%), By Treatment Type, 2017-2031F
  • Figure 98. Asia-Pacific Onychomycosis Market Share (%), By Indication, 2017-2031F
  • Figure 99. Asia-Pacific Onychomycosis Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 100. Asia-Pacific Onychomycosis Market Share (%), By Country, 2017-2031F
  • Figure 101. India Onychomycosis Market, By Value, in USD Billion, 2017-2031F
  • Figure 102. India Onychomycosis Market, By Volume, in Million Units, 2017-2031F
  • Figure 103. India Onychomycosis Market Share (%), By Treatment Type, 2017-2031F
  • Figure 104. India Onychomycosis Market Share (%), By Indication, 2017-2031F
  • Figure 105. India Onychomycosis Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 106. China Onychomycosis Market, By Value, in USD Billion, 2017-2031F
  • Figure 107. China Onychomycosis Market, By Volume, in Million Units, 2017-2031F
  • Figure 108. China Onychomycosis Market Share (%), By Treatment Type, 2017-2031F
  • Figure 109. China Onychomycosis Market Share (%), By Indication, 2017-2031F
  • Figure 110. China Onychomycosis Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 111. Japan Onychomycosis Market, By Value, in USD Billion, 2017-2031F
  • Figure 112. Japan Onychomycosis Market, By Volume, in Million Units, 2017-2031F
  • Figure 113. Japan Onychomycosis Market Share (%), By Treatment Type, 2017-2031F
  • Figure 114. Japan Onychomycosis Market Share (%), By Indication, 2017-2031F
  • Figure 115. Japan Onychomycosis Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 116. Australia Onychomycosis Market, By Value, in USD Billion, 2017-2031F
  • Figure 117. Australia Onychomycosis Market, By Volume, in Million Units, 2017-2031F
  • Figure 118. Australia Onychomycosis Market Share (%), By Treatment Type, 2017-2031F
  • Figure 119. Australia Onychomycosis Market Share (%), By Indication, 2017-2031F
  • Figure 120. Australia Onychomycosis Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 121. Vietnam Onychomycosis Market, By Value, in USD Billion, 2017-2031F
  • Figure 122. Vietnam Onychomycosis Market, By Volume, in Million Units, 2017-2031F
  • Figure 123. Vietnam Onychomycosis Market Share (%), By Treatment Type, 2017-2031F
  • Figure 124. Vietnam Onychomycosis Market Share (%), By Indication, 2017-2031F
  • Figure 125. Vietnam Onychomycosis Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 126. South Korea Onychomycosis Market, By Value, in USD Billion, 2017-2031F
  • Figure 127. South Korea Onychomycosis Market, By Volume, in Million Units, 2017-2031F
  • Figure 128. South Korea Onychomycosis Market Share (%), By Treatment Type, 2017-2031F
  • Figure 129. South Korea Onychomycosis Market Share (%), By Indication, 2017-2031F
  • Figure 130. South Korea Onychomycosis Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 131. Indonesia Onychomycosis Market, By Value, in USD Billion, 2017-2031F
  • Figure 132. Indonesia Onychomycosis Market, By Volume, in Million Units, 2017-2031F
  • Figure 133. Indonesia Onychomycosis Market Share (%), By Treatment Type, 2017-2031F
  • Figure 134. Indonesia Onychomycosis Market Share (%), By Indication, 2017-2031F
  • Figure 135. Indonesia Onychomycosis Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 136. Philippines Onychomycosis Market, By Value, in USD Billion, 2017-2031F
  • Figure 137. Philippines Onychomycosis Market, By Volume, in Million Units, 2017-2031F
  • Figure 138. Philippines Onychomycosis Market Share (%), By Treatment Type, 2017-2031F
  • Figure 139. Philippines Onychomycosis Market Share (%), By Indication, 2017-2031F
  • Figure 140. Philippines Onychomycosis Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 141. Middle East & Africa Onychomycosis Market, By Value, in USD Billion, 2017-2031F
  • Figure 142. Middle East & Africa Onychomycosis Market, By Volume, in Million Units, 2017-2031F
  • Figure 143. Middle East & Africa Onychomycosis Market Share (%), By Treatment Type, 2017-2031F
  • Figure 144. Middle East & Africa Onychomycosis Market Share (%), By Indication, 2017-2031F
  • Figure 145. Middle East & Africa Onychomycosis Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 146. Middle East & Africa Onychomycosis Market Share (%), By Country, 2017-2031F
  • Figure 147. Saudi Arabia Onychomycosis Market, By Value, in USD Billion, 2017-2031F
  • Figure 148. Saudi Arabia Onychomycosis Market, By Volume, in Million Units, 2017-2031F
  • Figure 149. Saudi Arabia Onychomycosis Market Share (%), By Treatment Type, 2017-2031F
  • Figure 150. Saudi Arabia Onychomycosis Market Share (%), By Indication, 2017-2031F
  • Figure 151. Saudi Arabia Onychomycosis Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 152. UAE Onychomycosis Market, By Value, in USD Billion, 2017-2031F
  • Figure 153. UAE Onychomycosis Market, By Volume, in Million Units, 2017-2031F
  • Figure 154. UAE Onychomycosis Market Share (%), By Treatment Type, 2017-2031F
  • Figure 155. UAE Onychomycosis Market Share (%), By Indication, 2017-2031F
  • Figure 156. UAE Onychomycosis Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 157. South Africa Onychomycosis Market, By Value, in USD Billion, 2017-2031F
  • Figure 158. South Africa Onychomycosis Market, By Volume, in Million Units, 2017-2031F
  • Figure 159. South Africa Onychomycosis Market Share (%), By Treatment Type, 2017-2031F
  • Figure 160. South Africa Onychomycosis Market Share (%), By Indication, 2017-2031F
  • Figure 161. South Africa Onychomycosis Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 162. By Treatment Type Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 163. By Indication Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 164. By Distribution Channel Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 165. By Region Map-Market Size (USD Billion) & Growth Rate (%), 2023